Back to discover
Drug

Rimegepant

Approved · EMA
Emerging researchLate-stage development

Also known as Nurtec.

RxNorm2282307ChEMBLCHEMBL2178422UNII997WVV895X
2
Research papers
12
Active clinical trials
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A PHASE 4, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF REDOSING OF RIMEGEPANT IN PARTICIPANTS 18 YEARS OF AGE OR OLDER FOR THE ACUTE TREATMENT OF MIGRAINE

Clinical trial2026-07-09Results expected Q2 2028 · ClinicalTrials.gov

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of Age

Clinical trial2026-07-09Results expected Q4 2031 · ClinicalTrials.gov

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE

Clinical trial2026-07-09Results expected Q4 2026 · ClinicalTrials.gov

AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE

Clinical trial2026-07-09Results expected Q4 2026 · ClinicalTrials.gov

Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age

Clinical trial2026-07-09Results expected Q3 2030 · ClinicalTrials.gov

A Prospective, Open-Label Study Evaluating the Effectiveness of Rimegepant ODT or Zavegepant Nasal Spray for Acute Treatment of Migraine in the Emergency Department

Clinical trial2026-06-25Results expected Q3 2027 · ClinicalTrials.gov

A Placebo Controlled, National, Multi-center, Randomized Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: The REVIVAL Study

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Rimegepant Plus Glofitamab and CD19 CAR-T Cell Therapy in Patients With High-Risk Relapsed/Refractory Large B-Cell Lymphoma

Clinical trial2026-05-29Results expected Q4 2028 · ClinicalTrials.gov

A Phase 4, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With a History of Inadequate Response to Oral Preventive Medications

Clinical trial2026-05-22Results posted · ClinicalTrials.gov

Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial.

Research2023-06-01The Lancet. Neurology

Approval: Vydura (EMA)

Regulatory2022-04-25EMA

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.

Research2019-07-13Lancet (London, England)

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Rimegepant
Aliases & brands
Nurtec
RxNorm CUI
2282307
ChEMBL ID
CHEMBL2178422
UNII
997WVV895X
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2022-04-25
Latest approval
2022-04-25
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2022-04-25Approval
Approval: Vydura (EMA)
Indication: Vydura is indicated for the Acute treatment of migraine with or without aura in adults; Preventative treatment of episodic migraine in adults who have at least 4 migraine attacks… Show full indication

Vydura is indicated for the Acute treatment of migraine with or without aura in adults; Preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

34 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
34
registered trials across all phases
LATEST COMPLETION 2025
12
Active studies
11
Recruiting
24
Late-stage (III+)
18
Completed
4
Discontinued
PHASE DISTRIBUTIONn = 34
Phase 11Phase 29Phase 2 / 32Phase 312Phase 410

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A PHASE 4, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF REDOSING OF RIMEGEPANT IN PARTICIPANTS 18 YEARS OF AGE OR OLDER FOR THE ACUTE TREATMENT OF MIGRAINE

RecruitingPH IVPfizern=4002028

Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US

RecruitingPH IVMedstar Health Research Instituten=602027

A Comparison of Rimegepant Orally Disintegrating Tablet (Nurtec ODT) to Rizatriptan Benzoate Orally Disintegrating Tablet (Maxalt MLT-ODT) in Adult Patients Presenting to the ED With Migraine Headache: Randomized, Double-Blind, Clinical Trial

RecruitingPH IVAntonios Likourezosn=802026

A Prospective, Open-Label Study Examining the Use of Rimegepant ODT 75 mg or Zavegepant Nasal Spray 10 mg for Acute Treatment of Migraine in the Emergency Department Setting

TerminatedPH IVIcahn School of Medicine at Mount Sinain=92026

A Phase 4, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With a History of Inadequate Response to Oral Preventive Medications

CompletedPH IVPfizern=9622025

Recent completions

Trials that read out recently, adding to the completed evidence base.

Cluster Headache Treatment With Rimegepant-Open Label Pilot Study

CompletedPH IIMayo Clinicn=202025

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rimegepant for Migraine Prevention in Chinese Participants

CompletedPH IIIPfizern=7872025

A Phase 4, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With a History of Inadequate Response to Oral Preventive Medications

CompletedPH IVPfizern=9622025

BHV3000-406 (C4951004): A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

CompletedPH IVPfizern=8132025

Rimegepant, a CGRP Antagonist, in the Treatment of Visceral Sensation and Chronic Abdominal Pain: A Pilot Study

CompletedPH IIMayo Clinicn=392025

A Pilot Study of Rimegepant in Moderate Plaque-type Psoriasis

CompletedPH IIWeill Medical College of Cornell Universityn=412024

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20192023
Major research themes2
Calcitonin Gene-Related Peptide1Migraine Disorders1
Journals, researchers & institutions
Top journals
  • Lancet (London, England)1
  • The Lancet. Neurology1
Leading researchers
  • Croop R2
  • Stock DA2
  • Conway CM1
  • Coric V1
  • Forshaw M1
  • Gao Y1
  • Goadsby PJ1
  • Guo A1
Leading institutions
free-text, unnormalised
  • Albert Einstein College of Medicine1
  • Changsha Central Hospital1
  • Chinese PLA General Hospital1
  • Kangbuk Samsung Hospital1
  • NIHR-Wellcome Trust King's Clinical Research Facility1
  • Nowon Eulji Medical Center1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.